C12N 2710/10271
Demonstrated in vivo effect
C12N2710/10271 (Demonstrated in vivo effect) appears on 4 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 5
- Assignees
- 3
- Inventors
- 9
- Latest grant
- 1 Sep 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 2 |
| 2018 | 0 | 0 |
| 2019 | 2 | 0 |
| 2020 | 1 | 0 |
By publication year.
Recent patents
- Vaccine in the form of a recombinant sero type 9 avian adenovirus vector1 Sep 2020US 10,758,608 B2Grupo Industrial Pecuario, S.A. De C.V.
- LPS vaccine7 May 2019US 10,279,025 B2The Chemo-Sero-Therapeutic Research Institute
- Fowl adenovirus vaccine5 Mar 2019US 10,220,088 B2Veterinarmedizinische Universitat Wien
- LPS vaccine24 May 2016US 9,345,756 B2The Chemo-Sero-Therapeutic Research Institute
- Lps vaccine5 Oct 2017US 2017/0281745 A1The Chemo-Sero-Therapeutic Research Institute
- Vaccine in the form of a recombinant sero type 9 avian adenovirus vector17 Aug 2017US 2017/0232096 A1Grupo Industrial Pecuario, S.A. De C.V.
- Lps vaccine11 Aug 2016US 2016/0228526 A1The Chemo-Sero-Therapeutic Research Institute
- Fowl Adenovirus Vaccine14 Jul 2016US 2016/0199484 A1Veterinarmedizinische Universitat Wien
- Lps vaccine26 Mar 2015US 2015/0086590 A1The Chemo-Sero-Therapeutic Research Institute
Most cited
By later US patents